Hardman Johnston Global Advisors LLC Has $21.77 Million Stock Position in Boston Scientific Corporation $BSX

Hardman Johnston Global Advisors LLC reduced its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 3.8% during the 4th quarter, HoldingsChannel.com reports. The firm owned 228,264 shares of the medical equipment provider’s stock after selling 9,089 shares during the period. Hardman Johnston Global Advisors LLC’s holdings in Boston Scientific were worth $21,765,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Burney Co. boosted its stake in Boston Scientific by 9.2% in the fourth quarter. Burney Co. now owns 14,090 shares of the medical equipment provider’s stock valued at $1,343,000 after buying an additional 1,188 shares in the last quarter. Altfest L J & Co. Inc. boosted its stake in Boston Scientific by 38.3% in the fourth quarter. Altfest L J & Co. Inc. now owns 17,376 shares of the medical equipment provider’s stock valued at $1,657,000 after buying an additional 4,814 shares in the last quarter. Coerente Capital Management acquired a new stake in Boston Scientific in the fourth quarter valued at about $423,000. Bouvel Investment Partners LLC boosted its stake in Boston Scientific by 1.5% in the fourth quarter. Bouvel Investment Partners LLC now owns 46,142 shares of the medical equipment provider’s stock valued at $4,400,000 after buying an additional 686 shares in the last quarter. Finally, Bartlett & CO. Wealth Management LLC boosted its stake in Boston Scientific by 33.9% in the fourth quarter. Bartlett & CO. Wealth Management LLC now owns 1,310 shares of the medical equipment provider’s stock valued at $125,000 after buying an additional 332 shares in the last quarter. 89.07% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the completion of the transaction, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.34% of the stock is owned by company insiders.

Boston Scientific Price Performance

Boston Scientific stock opened at $61.72 on Monday. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $91.72 billion, a PE ratio of 31.81, a P/E/G ratio of 0.95 and a beta of 0.78. Boston Scientific Corporation has a 12 month low of $60.59 and a 12 month high of $109.50. The stock has a 50-day moving average price of $71.47 and a two-hundred day moving average price of $88.00.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating the consensus estimate of $0.78 by $0.02. The firm had revenue of $5.29 billion during the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The business’s quarterly revenue was up 15.9% on a year-over-year basis. During the same period last year, the company earned $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on the company. National Bank Financial set a $115.00 price objective on Boston Scientific in a research note on Monday, February 2nd. Barclays reduced their price objective on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating on the stock in a research note on Tuesday, February 3rd. Mizuho reduced their price objective on Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Robert W. Baird reduced their price objective on Boston Scientific from $118.00 to $101.00 and set an “outperform” rating on the stock in a research note on Thursday, February 5th. Finally, Canaccord Genuity Group reduced their price objective on Boston Scientific from $112.00 to $109.00 and set a “buy” rating on the stock in a research note on Tuesday, February 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $104.05.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: FDA cleared Boston Scientific’s Asurys Fluid Management System (510(k)), a perioperative fluid-management product that expands the company’s procedural portfolio and supports recurring consumables revenue and long-term growth narrative. This type of clearance can help justify premium growth multiples if adoption follows. Boston Scientific (BSX) Receives FDA Clearance for Asurys Fluid Management System
• Neutral Sentiment: Street forecasts and FY2026 earnings expectations are being updated across outlets; investors should watch consensus revisions which can drive near-term volatility even if underlying fundamentals stay intact. Equities Analysts Offer Predictions for BSX FY2026 Earnings
• Neutral Sentiment: Sector moves and startup funding (e.g., E2’s $80M raise for thrombectomy tech) highlight ongoing competition and innovation in device segments where Boston Scientific competes; these developments are worth monitoring for market-share and M&A implications. E2 raises $80M to market thrombectomy platform
• Negative Sentiment: Multiple law firms have issued shareholder alerts and a securities class action has been filed, with a May 4, 2026 deadline for lead plaintiff motions. Consolidation of claims or a lead plaintiff could increase litigation costs, create disclosure risk, and pressure sentiment while the case proceeds. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: At least one major broker (Citigroup) has lowered expectations for BSX, which can prompt further analyst downgrades and price pressure if others follow. Monitor analyst notes for revised revenue/margin forecasts. Citigroup Has Lowered Expectations for Boston Scientific (NYSE:BSX) Stock Price

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.